Expression of angiogenic chemokines in ovarian clear cell carcinoma

Authors

  • Livia Quattrocchi,

    1. Department of Histopathology, Nottingham University Hospitals NHS Trust, Queen's Medical Centre Campus
    Search for more papers by this author
  • Melanie Sisson,

    1. Department of Histopathology, Nottingham University Hospitals NHS Trust, Queen's Medical Centre Campus
    Search for more papers by this author
  • Andrew Green,

    1. Division of Clinical Pathology
    Search for more papers by this author
  • Stewart G. Martin,

    1. Division of Clinical Oncology, School of Molecular Medical Sciences, University of Nottingham, City Hospital Campus, Nottingham, UK
    Search for more papers by this author
  • Lindy Durrant,

    1. Division of Clinical Oncology, School of Molecular Medical Sciences, University of Nottingham, City Hospital Campus, Nottingham, UK
    Search for more papers by this author
  • Suha Deen

    Corresponding author
    1. Department of Histopathology, Nottingham University Hospitals NHS Trust, Queen's Medical Centre Campus
      Professor Suha Deen, Department of Histopathology, Nottingham University Hospitals NHS Trust, Queen's Medical Centre Campus, Derby Road, Nottingham NG7 2UH, UK. Email: sdeen@doctors.org.uk
    Search for more papers by this author

Professor Suha Deen, Department of Histopathology, Nottingham University Hospitals NHS Trust, Queen's Medical Centre Campus, Derby Road, Nottingham NG7 2UH, UK. Email: sdeen@doctors.org.uk

Abstract

Aims:  The aim of this study was to assess the expression of angiogenic chemokines (CXCR4/CXCL12) and the vascular endothelial growth factor in ovarian clear cell carcinoma, comparing levels against those in ovarian high-grade serous carcinoma.

Material and Methods:  Tissue microarray samples from 136 cases of epithelial ovarian carcinoma (108 high-grade serous carcinoma and 28 clear cell carcinoma) were reviewed with World Health Organization histological criteria strictly applied to categorize cases according to histological subtype. Only cases without prior exposure to chemotherapy were included. Sections were stained with vascular endothelial growth factor, CXCR4, CXCL12 and assessed using conventional histological scoring (H-scoring).

Results:  Patients with clear cell carcinoma presented at an early stage of the disease (74% stage 1 and 2) and had a significantly better progression-free (P = 0.042) survival than those with high-grade serous carcinoma. Low expression profile of the tested markers was seen in cases of clear cell carcinoma contrary to that seen in high-grade serous carcinoma.

Conclusion:  The current study reports, for the first time, the difference in expression of a set of angiogeneic prognostic markers between clear cell carcinoma and high-grade serous carcinoma, offering a possible explanation for the apparent chemotherapy resistance. These results are relevant for the design of future clinical studies of first-line treatment for patients with ovarian clear cell carcinoma.

Ancillary